Daniel M. Jorgensen, MD, MPH, MBA

Dr. Jorgensen is an accomplished physician executive with more than 24 years of experience in the biopharmaceutical industry, in both small and large companies, public and private, including C-level positions for the past 11 years. In these roles, he has worked closely with a broad range of investors, strategic partners, and scientific experts, while building exceptional teams. His background includes comprehensive research, development, and commercialization experience for small molecules, biologics/vaccines, and devices across multiple therapeutic areas, particularly infectious diseases, immunology/inflammation, diabetes, and neuroscience. Prior to joining C-Path, Dr. Jorgensen was CEO of AxoProtego Therapeutics where he oversaw a biotechnology platform addressing neurodegeneration in areas of high unmet need. Earlier in his career, during his 10 years at Pfizer, Dr. Jorgensen was the Global Clinical Leader for azithromycin and was named Pfizer’s first Vaccine Development Team Leader, playing a key role in multiple FDA meetings, submissions, and approvals. Prior to joining Industry, Dr. Jorgensen was an Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control & Prevention (CDC), focusing on infectious disease outbreaks, vaccine accessibility, and refugee health, and thereafter, held several public health positions, including Montana State Medical Officer. Dr. Jorgensen was educated at Yale (BS); Univ. of Wisconsin (MD); Univ. of Washington (MPH); and Yale (MBA), with board certifications in Pediatrics, Infectious Diseases, and Preventive Medicine.